ReviewNature reviews. Cancer2014
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.
Review in Nature reviews. Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03160274 (Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions), which is not on this map. Cited by 277 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Who cites it
277 citing papers in PubMed, 1 synthesis or guideline pooled it, 537 citations in OpenAlex.
- Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Pooled it
- Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study.Frontiers in endocrinology · 2020Trial
- The utility of genetic testing for pheochromocytoma and paraganglioma.Proceedings (Baylor University. Medical Center) · 2026Article
- PPGLomics: an interactive platform for pheochromocytoma and paraganglioma transcriptomics.Endocrine-related cancer · 2026Article
- Comprehensive Genomic Analysis in Hereditary Adrenal and Extra-Adrenal Paragangliomas.Endocrine pathology · 2026Article
- Clinicopathological Features, Tumor Localization and Treatment Outcomes in Paraganglioma: A Single-Center Medical Oncology Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Pheochromocytoma and multicentric giant cell tumor of bone.Archives of endocrinology and metabolism · 2026Article
- Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage.Endocrine-related cancer · 2026Article
- Identifying TMEM127-deficient pheochromocytomas/paragangliomas via RET overexpression by immunohistochemistry.Research square · 2026Article
- From Tissue Architecture To Genetic Signature: Artificial intelligence-based Analysis of Reticulin Framework and Clinical Variables Predicts Molecular Cluster in Paragangliomas.Endocrine pathology · 2026Article
- PPGLomics: An Interactive Platform for Pheochromocytoma and Paraganglioma Transcriptomics.bioRxiv : the preprint server for biology · 2026Article
- Metastatic progression of pheochromocytoma and paraganglioma occurs via parallel evolution.NPJ precision oncology · 2026Article
- Surgical resection versus stereotactic radiosurgery for succinate dehydrogenase-related hereditary head and neck paragangliomas.Journal of neuro-oncology · 2026Article
- SDHB and CDK1 protein expression in metastatic pheochromocytoma and paraganglioma.Endocrine oncology (Bristol, England) · 2026Article
- Biochemical Diagnosis of Phaeochromocytoma and Paraganglioma in Children and Adolescents: A Retrospective Cohort Study.Clinical endocrinology · 2025Article
- Pathway coessentiality mapping reveals complex II is required for de novo purine biosynthesis in acute myeloid leukaemia.Nature metabolism · 2025Article
- FDA fast-track approval of belzutifan is a milestone in rare cancer therapy.Nature reviews. Endocrinology · 2025Article
- Article
- Clinical significance, prognosis, and risk model of SDHB expression loss and ERBB2 expression in pheochromocytoma and paraganglioma.Endocrine connections · 2025Article
- TheInternational journal of molecular sciences · 2025Article
217 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neuroendocrine tumours pheochromocytomas and paragangliomas carry the highest degree of heritability in human neoplasms, enabling genetic alterations to be traced to clinical phenotypes through their transmission in families. Mutations in more than a dozen distinct susceptibility genes have implicated multiple pathways in these tumours, offering insights into kinase downstream signalling interactions and hypoxia regulation, and uncovering links between metabolism, epigenetic remodelling and cell growth. These advances extend to co-occurring tumours, including renal, thyroid and gastrointestinal malignancies. Hereditary pheochromocytomas and paragangliomas are powerful models for recognizing cancer driver events, which can be harnessed for diagnostic purposes and for guiding the future development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.